期刊
HEPATOLOGY
卷 52, 期 6, 页码 2206-2215出版社
WILEY
DOI: 10.1002/hep.24042
关键词
-
资金
- GSK
- Astellas and Gilead
Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials (HEPATOLOGY 2010,52 2206-2215)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据